Skip to main
We’re doing some system maintenance
  1. Home
  2. Stocks
  3. Sophiris Bio
SPHS

Buy Sophiris Bio (SPHS) Stock

SPHS
See SPHS stock price and Buy/Sell Sophiris Bio with any amount of money. Discuss news and analysts' price predictions with the investor community.
Sign up to start investing
SPHS

Sophiris Bio (SPHS)

About Sophiris Bio (SPHS)

Sophiris Bio Inc. (NASDAQ: SPHS) is a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), which it believes is an unsatisfied patient population with significant market potential. Sophiris is currently developing PRX302 for the treatment of BPH symptoms which is designed to be as efficacious as pharm...Read more
Market Cap
1 Year High
$0.03
Volume
1 Year Low
Price to Earnings Ratio
Open
Dividend Rate
High
Dividend Yield
Low

Community

People who own or watch SPHS stock

Sophiris Bio Stock News

Sophiris Bio stock rating

What analysts recommend for SPHS stock, on a scale from 1 (buy) to 5 (sell).
Buy
Sell
1

Sophiris Bio price target

What analysts think SPHS will be worth
Low $0
High $3.75
Current $0
Target $3.75

Events

List of events that could affect SPHS stock.
07Nov

Earnings data Q3 2019

19May

Earnings data Q1 2020

Sophiris Bio earnings

The value each share was expected to gain vs. the value that each share actually gained
0
-0.07
-0.15
-0.22
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Q4 2020

Expected EPS
Q4 2020
-$0.22
Actual EPS
Q4 2020

Buy Sophiris Bio (SPHS) Stock

SPHS
See SPHS stock price and Buy/Sell Sophiris Bio with any amount of money. Discuss news and analysts' price predictions with the investor community.
Sign up to start investing

Community

People who own or watch SPHS stock
  • PDiggy97 avatar
  • noloss avatar
  • Pharah avatar
  • amyjo avatar
  • ballz avatar
Check the background of this firm on FINRA’s BrokerCheck.

© Copyright 2022 Public Holdings, Inc. All Rights Reserved.

Securities are offered to self-directed customers by Open to the Public Investing, Inc. (“Open to the Public Investing”), a registered broker-dealer and member of FINRA & SIPC. Additional information about your broker can be found by clicking here. Open to Public Investing is a wholly-owned subsidiary of Public Holdings Inc. (“Public Holdings”). This is not an offer, solicitation of an offer or advice to buy or sell securities, or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered. Securities products offered by Open to the Public Investing are not FDIC insured.

Cryptocurrency execution and custody services are provided by Apex Crypto LLC (NMLS ID 1828849) through a software licensing agreement between Apex Crypto LLC and Public Crypto LLC. Apex Crypto is not a registered broker-dealer or a member of SIPC or FINRA. Cryptocurrencies are not securities and are not FDIC or SIPC insured. Apex Crypto is licensed to engage in virtual currency business activity by the New York State Department of Financial Services. Please ensure that you fully understand the risks involved before trading: Legal Disclosures

Commission-free trading of stocks and ETFs refers to $0 commissions for Open to the Public Investing self-directed individual cash brokerage accounts that trade the U.S. listed securities electronically. Keep in mind, that other fees such as regulatory fees, Premium subscription fees, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Open to the Public Investing’s Fee Schedule to learn more.

All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns.